Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
about
A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in JapanJapanese Physicians' Views on Drug Post-Marketing Surveillance.Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional studyDelays in psychiatric drug development in Japan.Analysis of regulatory review times of new drugs in Japan: association with characteristics of new drug applications, regulatory agency, and pharmaceutical companies.Relationship between drug lag and factors associated with clinical trials in Japan.Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States.Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?Japan lags behind the UK in neurological drug approvals.Potential factors correlating to the PMDA's decision to waive Japanese Phase 2 and 3 studies for oncology drugs New Drug Application in Japan.Analysis of new drugs whose clinical development and regulatory approval were hampered during their introduction in Japan.Pharmacy Students' Knowledge and Attitude toward Registration Trials and Clinical Research: A Survey in a Japanese University Hospital.Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.Fatal adverse drug reactions of anticancer drugs detected by all-case post-marketing surveillance in Japan.
P2860
Q35284247-B382D766-FC58-48D1-B429-68FD2BA0CB8AQ36223753-E1EC8CFC-CFE4-44E4-8C29-7CA8EE9E5EAFQ37566655-68DFFE02-1259-4520-91AE-94EC06092DBAQ37948093-AF39436D-CA2B-46FE-AD31-EF957D9EFD37Q38021813-0047C0CD-CC81-43B3-A6B3-61885A836670Q38247002-83311AED-913B-4E8C-821A-5CA5AD35FDC9Q38308329-2F13CC75-A8CE-4569-9146-F60F4E9C07BFQ38403104-37242E24-BDA9-42A3-BD91-23CD2E92F3B8Q42635642-4903643D-41D0-4952-AC2B-EB642BB19AC9Q43965904-89F0E6CA-6FD9-45B0-B26F-4836DD25A7D0Q45806323-9FACAD5E-BA9A-4C22-A7FC-B245787A068EQ47160726-41E17CCD-1F76-49BE-9F6A-3758E37DE506Q48005672-389F2243-3086-4603-AA1C-0373F555F89DQ50949890-542992BE-308C-4F2B-B74E-3522E3431F5D
P2860
Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
@en
Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
@nl
type
label
Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
@en
Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
@nl
prefLabel
Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
@en
Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
@nl
P2860
P1476
Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2710.2009.01099.X
P577
2010-06-01T00:00:00Z